Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/26/16	₩3,625.00	-6.57%	2,41,230
15/26/15	₩3,880.00	+8.08%	2,42,777
14/26/14	₩3,590.00	-8.77%	4,21,874
13/26/13	₩3,935.00	-7.63%	3,82,836
10/26/10	₩4,260.00	+11.23%	4,98,274

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 16/07/2026			5-day change	1st Jan Change
3,625.00 ^KRW	-6.57%		-5.35%	-47.31%

13/04	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
03/04	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

Market Cap	16TCr 11Cr 9.62Cr 8.88Cr 8.19Cr 15Cr 1.06TCr 16Cr 106.16Cr 42Cr 519.45Cr 41Cr 40Cr 1.79TCr	P/E 2024	-4.17x	P/E 2025	-33.5x
Enterprise Value	15TCr 9.81Cr 8.57Cr 7.91Cr 7.29Cr 14Cr 944.94Cr 14Cr 95Cr 37Cr 462.79Cr 37Cr 36Cr 1.59TCr	EV / Sales 2024	1.31x	EV / Sales 2025	8.97x
Free-Float	82.79%	Yield 2024 *	-	Yield 2025	-

13/04	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
03/04	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
13/03	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
22/25/22	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
21/25/21	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
11/25/11	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
28/25/28	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
24/25/24	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
24/25/24	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
24/25/24	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
19/24/19	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
17/24/17	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24/24/24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI

1 day	-6.57%
1 week	-5.35%
Current month	-6.09%
1 month	-34.57%
3 months	-48.87%
6 months	-48.21%
Current year	-47.31%

Genome & Company Share Price

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

Valuation: Genome & Company

Chart: Genome & Company

Latest news : Genome & Company

Quotes and Performance

Course Extremes

Managers and Directors: Genome & Company

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	3,455	4,375
1 month	3,435	5,590
Current year	3,435	10,180
1 year	2,440	10,180
3 years	2,170	10,180
5 years	2,170	28,800
10 years	2,170	47,500

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	24/09/2015
Ji-Soo Bae CEO	Chief Executive Officer	55	24/09/2015

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	24/09/2015
Han-Su Park BRD	Director/Board Member	53	24/09/2015
Yu-Seok Hong BRD	Director/Board Member	62	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/05/25	Sang-Kyun Kim	Free	Director	40,000	0.1287%
09/05/25	Byung-Gyu Park	Free	Public Communications Manager	50,000	0.1608%
09/05/25	Ji-Soo Bae	Don	Founder	90,000	0.2895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	-6.57%	-5.35%	+19.05%	-52.30%	11Cr
LONZA GROUP AG	-1.29%	-2.54%	-0.35%	+4.30%	4.97TCr
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	3.81TCr
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	3.53TCr
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	3.51TCr
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	2.72TCr
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	1.61TCr
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	1.54TCr
EUROFINS SCIENTIFIC SE	+1.12%	+2.15%	+16.24%	+19.12%	1.39TCr
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	1.3TCr
Average	-0.64%	-2.00%	+59.34%	+81.75%	2.44TCr
Weighted average by Cap.	-0.15%	-0.65%	+75.18%	+119.65%

	2024	2025
Net sales	2.77TCr 1.87Cr 1.63Cr 1.5Cr 1.39Cr 2.61Cr 179.68Cr 2.67Cr 18Cr 7.07Cr 88Cr 7.01Cr 6.85Cr 302.94Cr	2.46TCr 1.65Cr 1.44Cr 1.33Cr 1.23Cr 2.32Cr 159.23Cr 2.37Cr 16Cr 6.27Cr 78Cr 6.21Cr 6.07Cr 268.46Cr
Net income	-2.01TCr -1.35Cr -1.18Cr -1.09Cr -1.01Cr -1.89Cr -130.25Cr -1.94Cr -13Cr -5.13Cr -64Cr -5.08Cr -4.97Cr -219.6Cr	-642.81Cr -43.23L -37.78L -34.86L -32.13L -60.56L -42Cr -61.91L -4.17Cr -1.64Cr -20Cr -1.62Cr -1.59Cr -70Cr
Net Debt	-4.89TCr -3.29Cr -2.87Cr -2.65Cr -2.44Cr -4.61Cr -316.73Cr -4.71Cr -32Cr -12Cr -155.12Cr -12Cr -12Cr -534Cr	-1.79TCr -1.2Cr -1.05Cr -96.87L -89.29L -1.68Cr -115.68Cr -1.72Cr -12Cr -4.55Cr -57Cr -4.51Cr -4.41Cr -195.04Cr